Coherus Oncology reduces headcount by about 30%
CHRS•Coherus Oncology cut its headcount by about 30% and expects core cash burn to decrease by $6 million to $7 million quarterly over the next two quarters.
1. Workforce and cash burn
Coherus Oncology reduced its headcount by about 30%, according to an SEC filing. The company expects core cash burn to decrease by $6 million to $7 million quarterly over the next two quarters.
